[5-FU/ADR/MMC combined hepatic infusion in liver metastases from gastric cancer].

Twenty patients with liver metastases from gastric cancer judged non-resectable and the factors limiting their survival were treated with 5-fluorouracil (5-FU), adriamycin (ADR) and mitomycin C (MMC) combined hepatic arterial infusion chemotherapy. The catheter was placed into the hepatic artery, via the left subclavian artery in every case, and 5-FU 334 mg/m2 qw, ADR 20 mg/m2 q4w, MMC 2.7 mg/m2 q2w was administered bolusly. Myelo-suppression (WBC less than 2,000 or platelet less than 50,000) occurred in 25% of the patients, but this therapy was tolerable in all patients without major complication. The response rate in evaluable cases by CT-scan was 76.5% (4CR + 9PR/17), and 50% survival was 407 days. A significant correlation between the existence of extra-hepatic lesions and 50% survival (extra-hepatic lesions (-): 196 days vs (+): 464 days) was noted. The comparison between responder and non-responder in terms of 50% survival and the cause of death showed the importance of control of liver metastases for improved survival.